185
0 Kommentare
Novo Nordisk's sales increased by 22% in Danish kroner and by 24% at constant exchange rates to DKK 65.3 billion in the first three months of 2024 - Seite 2
185 
0 KommentareOn 2 May 2024 at 13.00 CEST, corresponding to 07.00 am EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube.
| Contacts for further information: | |
| Media: | |
|
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com |
Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
|
Daniel Muusmann Bohsen +45 3075 2175 dabo@novonordisk.com |
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com |
|
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com |
Mark Joseph Root (US) +1 848 213 3219 mjhr@novonordisk.com |
|
Sina Meyer +45 3075 6656 azey@novonordisk.com |
Frederik Taylor Pitter +45 3075 8259 fptr@novonordisk.com |
|
Ida Melvold Gjøsund +45 3077 5649 idmg@novonordisk.com |
Company announcement No 35 / 2024
Lesen Sie auch
Attachment
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
URL kopieren
Per E-Mail teilen
Artikel drucken
Artikel zu den Werten
Auch bei Lesern beliebt
